Cinnarizine of a tablet of 25 mg No. 50

General characteristics. Structure:

25 mg of cinnarizine as active agent; excipients -
potato starch, polyvinylpirrolidone low-molecular (povidone), magnesium stearate, lactose, aerosil (silicon dioxide colloid)

Description: Tablets of color, white or white with a creamy shade, ploskotsilindrichesky with a facet.

Indications to use:

Symptoms of cerebrovascular insufficiency (dizziness, sonitus, headache, memory disturbances, decrease in concentration of attention), vestibular disturbances (including Menyer's disease: dizziness, a sonitus, a nystagmus, nausea and vomiting of a labyrinth origin), prevention of kinetoz ("a road disease" - sea and aeroembolism), migraine (prevention of attacks).
Disturbances of peripheric circulation: a Raynaud's disease, the "alternating" lameness, a Crocq's disease, trophic disturbances (including trophic and varicose ulcers).

Route of administration and doses:

Inside, after food. At insufficiency of cerebral circulation: on 25 mg three times a day.
At disturbance of peripheric circulation - on 50-75 mg three times a day. At vestibular disturbances - on 25 mg three times a day. The maximum recommended dose should not exceed 225 mg (9 tablets) a day. A course of treatment from several weeks to several months.
At a kinetoza (a "road" disease): the adult - on 25 mg for half an hour before the road (if necessary repeated reception of 25 mg in 6 hours), for children of 5 years – ½ doses, recommended to adults. At high sensitivity to drug treatment is begun about ½ doses, increasing it gradually.

Features of use:

The patient with Parkinson's disease drug is appointed only in case advantages of treatment surpass by cinnarizine in the importance possible deterioration in a current of a basic disease.
In an initiation of treatment can cause drowsiness therefore alcohol intake and simultaneous use of depressants of the central nervous system demands care. Due to the antihistaminic effect purpose of cinnarizine should be stopped in 4 days prior to conducting allergy skin test. Cinnarizine can affect result at anti-doping control of athletes (false positive result). At a lactose intolerance it is necessary to consider that one tablet contains 175 mg of lactose.

Influence on ability to drive the car and other working mechanisms:
Drowsiness development, especially in an initiation of treatment therefore it is necessary to be careful during the driving of motor transport and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions is possible. At prolonged use carrying out control laboratory inspection of function of a liver, kidneys is recommended, to peripheral blood.

Side effects:

From a nervous system: drowsiness, fatigue, headache, extrapyramidal frustration (tremor of extremities and increase in a muscle tone, hypokinesia), depression.
From the alimentary system: dryness in a mouth, pain in epigastric area, dyspepsia, cholestatic jaundice.
From integuments: perspiration, development of a volchanochnopodobny syndrome, red flat deprive (extremely seldom), skin rash.
Others: allergic reactions, increase in body weight.

Interaction with other medicines:

Strengthens the oppressing action on the central nervous system of alcohol, sedatives, tricyclic antidepressants. Due to the existence of antihistaminic effect, cinnarizine can affect result of anti-doping control of athletes (a false positive take), and also can level positive reactions when conducting skin diagnostic tests (in 4 days prior to a research treatment should be cancelled).

Contraindications:

Hypersensitivity, pregnancy, the lactation period, children's age up to 5 years.
With care at Parkinson's disease.

Overdose:

Symptoms: strengthening of expressiveness of side effects, lowering of arterial pressure, vomiting, coma. Treatment: the specific antidote does not exist, a gastric lavage, reception of absorbent carbon, symptomatic therapy.

Storage conditions:

List B. In the dry, protected from light place. To store in the place, unavailable to children. Period of validity: 2 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Tablets of 25 mg. On 10 tablets in a blister strip packaging. On 5 blister strip packagings together with the application instruction in a pack from a cardboard.